AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Ocugen, Inc. Director's Dealing 2014

Dec 3, 2014

32915_dirs_2014-12-02_2cf52470-ef57-457f-8070-311056cd36c8.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: HISTOGENICS CORP (HSGX)
CIK: 0001372299
Period of Report: 2014-12-02

Reporting Person: McArdle Kevin (Chief Financial Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Employee Stock Option (Right to Buy)	$0.76	2022-08-14	Common Stock (19179)		Direct
Employee Stock Option (Right to Buy)	$0.76	2023-05-16	Common Stock (7263)		Direct

Footnotes

F1: This option vests over four years of continuous service following July 20, 2012, with 25% vesting upon completion of one year of service and in 36 equal monthly instalments thereafter.

F2: Reflects a 10.804-to-1 reverse stock split effected on November 14, 2014.

F3: This option vests over four years of service following May 17, 2013, with 25% vesting upon completion of one year of service and in 36 equal monthly instalments thereafter.